<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00019110</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064330</org_study_id>
    <secondary_id>NCI-95-C-0154</secondary_id>
    <secondary_id>NCI-T94-0134N</secondary_id>
    <nct_id>NCT00019110</nct_id>
    <nct_alias>NCT00001441</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer</brief_title>
  <official_title>VACCINE THERAPY AND DETECTION OF IMMUNOLOGIC RESPONSES WITH HUMAN PAPILLOMAVIRUS 16 E6 AND E7 PEPTIDES IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED CERVICAL CANCER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from certain human papillomaviruses may be able to help the body to&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of human papillomavirus vaccine therapy in&#xD;
      treating patients who have advanced or recurrent cancer of the cervix, vagina, penis, anus,&#xD;
      esophagus, or head and neck.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether endogenous cellular immunity to the viral oncoproteins human papilloma&#xD;
           virus 16 (HPV16) E6 and E7 is present in patients with advanced or recurrent carcinoma&#xD;
           of the cervix or other carcinomas that carry HPV16.&#xD;
&#xD;
        -  Determine whether vaccination with antigen-presenting cells pulsed with synthetic&#xD;
           peptide corresponding to the tumor's HPV16 E6 or E7 peptide can induce or boost patient&#xD;
           cellular immunity to that particular peptide.&#xD;
&#xD;
        -  Determine the type and characteristics of the cellular immunity generated in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine whether in vivo T cells generated specifically against HPV16 E6 or E7 peptide&#xD;
           can be cloned and expanded in vitro against the corresponding peptide.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to disease category as defined by the following:&#xD;
&#xD;
        -  Stratum A: Stage III cervical cancer not previously treated with appropriate&#xD;
           radiotherapy; stage IV or recurrent cervical cancer; or other advanced tumors that&#xD;
           harbor human papilloma virus 16 (HPV16) such as anogenital, esophageal, or head and neck&#xD;
           cancers.&#xD;
&#xD;
        -  Stratum B: Stage III cervical cancer previously treated with standard therapy with no&#xD;
           evidence of residual disease. Vaccination in this group is given as adjuvant therapy.&#xD;
&#xD;
      Patients are assigned to receive HPV E6 or E7 peptide by the principal investigator.&#xD;
      Peripheral blood mononuclear cells (PBMC) (antigen presenting cells) are harvested and&#xD;
      treated in vitro with sargramostim (GM-CSF) and pulsed with HPV16 E6 or E7. Patients receive&#xD;
      vaccination with HPV16 E6 or E7 pulsed PBMC IV over 1-2 minutes during weeks 1, 3, 7, and 11&#xD;
      for a total of 4 vaccinations. Treatment continues in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients who achieve complete response (CR) continue treatment for a&#xD;
      maximum of 1 year past CR.&#xD;
&#xD;
      Patients are followed at 1 month.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40-46 patients (at least 28 patients for stratum A and 12 for&#xD;
      stratum B) will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1995</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Anal Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Penile Cancer</condition>
  <condition>Vulvar Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>human papillomavirus 16 E7 peptide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>synthetic human papillomavirus 16 E6 peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven stage III, IV, or recurrent carcinoma of the cervix or other&#xD;
             tumor that carries human papilloma virus 16 (HPV16) such as other anogenital (vulvar,&#xD;
             penile, and anal), esophageal, and head and neck cancers&#xD;
&#xD;
          -  HLA-A2.1 positive&#xD;
&#xD;
          -  Patients with tumors other than cervical cancer must have no other therapeutic options&#xD;
&#xD;
          -  Fresh tissue or paraffin block available for HPV genome detection and typing (optional&#xD;
             for cervical cancer)&#xD;
&#xD;
          -  No history of CNS metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGPT no greater than 4 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  No autoimmune disease, e.g.:&#xD;
&#xD;
               -  Systemic lupus erythematosus&#xD;
&#xD;
               -  Multiple sclerosis&#xD;
&#xD;
               -  Ankylosing spondylitis&#xD;
&#xD;
               -  HIV negative&#xD;
&#xD;
          -  Responsive to 1 of the following skin test antigens:&#xD;
&#xD;
               -  Mumps Trichophyton&#xD;
&#xD;
               -  Candida Tetanus&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No active infection requiring antibiotics&#xD;
&#xD;
          -  No weight loss greater than 20% within the past 6 months&#xD;
&#xD;
          -  No other active malignancy except basal cell skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 4 weeks since prior steroids and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from the toxic effects of prior therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry L. Gause, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962-1956</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0587</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 1999</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2015</last_update_posted>
  <keyword>stage IV anal cancer</keyword>
  <keyword>recurrent anal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IV cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage III vulvar cancer</keyword>
  <keyword>stage IVB vulvar cancer</keyword>
  <keyword>recurrent vulvar cancer</keyword>
  <keyword>stage III penile cancer</keyword>
  <keyword>stage IV penile cancer</keyword>
  <keyword>recurrent penile cancer</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>metastatic squamous neck cancer with occult primary squamous cell carcinoma</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Vulvar Neoplasms</mesh_term>
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

